Evidence map›Paper›PMID 42150891›Full record

ArticleBritish journal of haematology2026

Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile.

Barbara J McClure, John Toubia, Charlotte E J Toomes, O Giles Best, Angelina Yong, Cindy H Lee, Claudine S Bonder, Chung Hoow Kok

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Barbara J McClureCentre for Cancer Biology, College of Health, Adelaide University and SA Pathology, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-5201-4127
John ToubiaCentre for Cancer Biology, College of Health, Adelaide University and SA Pathology, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-5135-6504
Charlotte E J ToomesFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.ORCID https://orcid.org/0000-0001-7458-836X
O Giles BestFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.ORCID https://orcid.org/0000-0003-2685-3880
Angelina YongDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.ORCID https://orcid.org/0009-0003-5206-089X
Cindy H LeeDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
Claudine S BonderCentre for Cancer Biology, College of Health, Adelaide University and SA Pathology, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0001-9875-967X
Chung Hoow KokCentre for Cancer Biology, College of Health, Adelaide University and SA Pathology, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-3181-7852

Funding

National Health and Medical Research Council GNT2013460
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

desmoglein‐2multiple myelomaprognostic biomarker

Identifiers

PMID42150891
PMCPMC13340476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.